Visiongain Publishes Advanced Therapy Medicinal Products (ATMP) Market Report 2021-2031
24 November 2020
Visiongain has published a new report on Advanced Therapy Medicinal Products (ATMP) Market Report 2021-2031: Forecasts by Therapy Products. Regional and Leading National Market Analysis PLUS Analysis of Leading ATMP Companies AND COVID-19 Recovery Scenarios.
Global ATMP market was valued at US$ x billion in 2021 and is projected to reach at a market value of US$ xx billion by 2031. Currently, the ATMP market is at a nascent stage and is expected to flourish during near future owing to increasing research and development activities and rising use of ATMP therapy products in treatment areas with low or no alternative treatment options support the market growth. In addition, advancements in biological therapies, rising preference for personalised medicine and developing application areas are some of the other factors driving the growth of the market.
COVID-19 Impact on Global ATMP Market
The impact of COVID-19 pandemic is there on almost all the sectors and assessing its impact on the market would be uncertain as there is no knowledge about how long this pandemic stay would. Visiongain believes that considering all the factors there can be four scenarios in which the global market can react to the current crisis and that can be ‘V’ shaped recovery, ‘U’ shaped recovery, ‘L’ shaped recovery and ‘W’ shaped recovery. The functioning of the ATMP was regular during the pandemic situation as the patients continued to benefit from the cell and gene therapies. In addition, the clinical progress of ATMP also continued but with new obstacles caused due to the pandemic and its effects. Many global ATMP companies reported challenges in clinical trial execution, including patient recruitment, enrolment, data collection and/or follow-up. In addition, managing and reacting to the ongoing public health crisis caused by COVID-19 has become the priority for many policymakers, regulators, and public sector payors. Thus, this could result in a delay for cell, gene, and tissue-based therapy product candidates outside of the COVID-19 space.
Regulations of ATMP is at a very initial stage and is constantly developing. Manufacturers are continuously engaged in working on investigational new drug (IND) application for the treatment of niche and rare diseases. In addition, there is a rising use of advanced therapy medicinal products among the patients suffering from life-threatening diseases owing to its ability to improve quality of life and health of the patient. Advanced therapies are recommended for those rare diseases which have very little or no alternative treatment options. Thus, positive impact of the treatment option on the health of the patients is one of the prime factors driving the growth of the advanced therapy medicinal products market during the forecast period.
The prevalence of various chronic diseases such as diabetes, cancer, cardiovascular diseases and genetic diseases such as cystic fibrosis and others is rising globally. Cardiovascular diseases are the most prevalent cause of death worldwide. According to a report published by the W.H.O (World Health Organization) cardiovascular diseases will cause approximately 25 million deaths by 2030. Rising prevalence of lifestyle habits such as growing number of global smokers, rising incidences of obesity and dietary irregularities are responsible for the growth of cardiovascular disease prevalence in the world. Furthermore, the number of congenital heart disease patients is on a constant rise and this acts as a growth driver for the market.
Trends in ATMP development offer opportunities to the manufacturers owing to increasing health benefits. Biologics account for around a third of pharmaceutical pipelines - this proportion will rise strongly in the coming 10 years. Although the majority of these new advanced therapy products are being developed in the US and EU, companies will look to take advantage of low-cost clinical trials in emerging markets. Other drug development trends include the increased development of highly potent, targeted products for chronic indications, such as cancer, lung cancer and other. The increased development in treatment areas where there are less or no treatment options. The additional variability means smaller providers can compete by offering specialised services. CMOs in the US and EU will benefit from these development trends, as these companies have the greatest experience in manufacturing potent products.
Some of the key players operating in the global ATMP market are Gilead Lifesciences, Spark Therapeutics, Inc., Celgene Corporation, PHARMICELL Co., Ltd., Organogenesis Ltd., MEDIPOST, JCR Pharmaceuticals, Co., Ltd. among others. These key players are focusing on developing and commercialising key and innovative therapy products in critical application areas helps them to gain competitive advantage in this lucrative market. Also, many companies are marking their presence in this emerging market with the acquisition of small and emerging companies engaged in developing advanced therapy medicinal products.
Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to firstname.lastname@example.org or call her on +44 (0) 20 7549 9987.
Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports focusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.
Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.
Visiongain Publishes eClinical Solutions Market Report 2023-2033
The global eClinical Solutions market was valued at US$8.03 billion in 2022 and is projected to grow at a CAGR of 13.09% during the forecast period 2023-2033.
17 March 2023
Visiongain Publishes Therapeutic Respiratory Devices Market Report 2023-2033
The global Therapeutic Respiratory Devices market was valued at US$59.49 billion in 2022 and is projected to grow at a CAGR of 8.02% during the forecast period 2023-2033.
15 March 2023
Visiongain Publishes Regenerative Medicine Market Report 2023-2033
The global Regenerative Medicine market was valued at US$ 50.37 billion in 2022 and is projected to grow at a CAGR of 18.40% during the forecast period 2023-2033.
10 March 2023
Visiongain Publishes Sleep Tech Market Report 2023-2033
The global Sleep Tech market was valued at US$16.08 billion in 2022 and is projected to grow at a CAGR of 22.6% during the forecast period 2023-2033.